Prolonged coma from refractory status epilepticus. 2006

Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
Critical Care Service, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

OBJECTIVE Status epilepticus is a life-threatening medical condition. In its most severe form, refractory status epilepticus (RSE) seizures may not respond to first and second-line anti-epileptic drugs. RSE is associated with a high mortality and significant medical complications in survivors with prolonged hospitalizations. METHODS We describe the clinical course of RSE in the setting of new onset lupus in a 31-year-old male who required prolonged barbiturate coma. RESULTS Seizure stopped on day 64 of treatment. Prior to the resolution of seizures, discussion around withdrawal of care took place between the physicians and patient's family. Medical care was continued because of the patient's age, normal serial MRI studies, and the patient's reversible medical condition. CONCLUSIONS Few evidence-based data exist to guide management of RSE. Our case emphasizes the need for continuous aggressive therapy when neuroimaging remains normal.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D012032 Refractory Period, Electrophysiological The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state. Period, Neurologic Refractory,Periods, Neurologic Refractory,Refractory Period, Neurologic,Tetanic Fade,Vvedenskii Inhibition,Wedensky Inhibition,Inhibition, Vvedenskii,Inhibition, Wedensky,Neurologic Refractory Period,Neurologic Refractory Periods,Neuromuscular Fade,Neuromuscular Transmission Fade,Refractory Period, Neurological,Refractory Periods, Neurologic,Electrophysiological Refractory Period,Electrophysiological Refractory Periods,Fade, Neuromuscular,Fade, Neuromuscular Transmission,Fade, Tetanic,Neurological Refractory Period,Neurological Refractory Periods,Refractory Periods, Electrophysiological,Refractory Periods, Neurological,Transmission Fade, Neuromuscular
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003128 Coma A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION. Comatose,Pseudocoma,Comas,Pseudocomas
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
February 1995, Critical care medicine,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
December 1956, Canadian Medical Association journal,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
October 2016, Therapeutic advances in drug safety,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
April 1984, Critical care medicine,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
September 1999, Critical care medicine,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
December 2018, Journal of epilepsy research,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
April 2015, Critical care (London, England),
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
July 2002, Anesthesiology,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
May 2010, Clinical neuropharmacology,
Saqib I Dara, and Lori A Tungpalan, and Edward M Manno, and Vivien H Lee, and Kevin G Moder, and Mark T Keegan, and Jimmy R Fulgham, and Daniel R Brown, and Keith H Berge, and Francis X Whalen, and Tuhin K Roy
October 1985, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!